
Men's Health At Work: A Silent Threat To Culture And Productivity
Men's health in the workplace is a silent issue brewing.
In Corporate America, you'll rarely hear male leaders admit they "need a break" or openly ask for help. Yet behind the scenes, many high-performing men are silently burning out, neglecting their well-being, and pushing onward until something breaks. Men's health is lagging behind that of women.
As of 2023, U.S. men live, on average, 5.3 years fewer than women—75.8 years compared to 81.1. As it pertains to the workplace, according to the Journal of Occupational and Environmental Medicine, psychological distress in men drives $8,432 per person annually in presenteeism losses and $2,796 in absenteeism, which is double the impact seen in women.
June may be Men's Health Month, but for corporate America, men's health needs a 365-day focus. The cost of ignoring it is significant: diminished productivity, increasing healthcare claims, leadership attrition, and untapped potential not realized. Addressing this requires reframing men's health and how organizations approach performance, well-being, and leadership sustainability, starting with these three foundational shifts.
Rest Doesn't Equate To Weakness Or Lower Ambition
In many high-pressure environments, rest is viewed as a luxury or, worse, a risk. Taking a break can feel like you're falling behind. This mentality quietly undermines leaders' ability to operate at their highest level.
Just as athletes suffer when recovery is skipped, so too do executives. When rest and circadian-aligned living are neglected, judgment erodes, creativity stagnates, and leaders become reactive rather than responsive. As burnout and retention strategist Chazz Scott shared, "Most people can't say, 'I took a break today and still felt successful.'" That quiet guilt, he noted, is deeply embedded in many male leaders and often stems from inherited beliefs that rest equals weakness.
However, the reality is the opposite. Rest, recovery, and restoration aren't the enemies of ambition. Instead, they're essential components of your optimal performance infrastructure. Ignoring these pillars doesn't just affect the leader; it affects everyone downstream. Leaders can build systems and cultures that support performance and recovery through:
Well-Being Isn't A One-Size-Fits-All Equation
There's been a much-needed shift toward prioritizing well-being in the workplace. However, most initiatives still fall short. While meditation apps and fitness challenges are well-intentioned, they often miss the mark, especially for male leaders navigating unique physiological, cultural, and socioeconomic stressors.
Health risks are not distributed equally. Black men, for instance, face significantly higher rates of hypertension, cardiovascular disease, and chronic stress, regardless of income level or professional title. Potential reasoning for this is, in some circles, attributed to what researchers call the weathering effect: the cumulative toll of enduring racialized stress over time, which accelerates biological aging and worsens long-term health outcomes.
As Justin Grant, author of Company Men: A Wellness Guide for Black Men in Corporate America, shares, the higher Black men rise in corporate spaces, the more likely they are to experience anxiety, isolation, and declining health. And they're not alone. Latino, Asian, and even first-generation professionals each face distinct challenges that generic wellness programs don't address. A more precise and culturally strong wellness strategy might start with:
Guard Your Mind And Don't Marginalize Yourself
For many male leaders, performance and identity become inseparable. Output becomes an ever-growing proxy for self-worth. Titles become personalities. And over time, the line between the person and position blurs. In this environment, mental health isn't just about managing stress. It's about preserving a sturdy sense of self. As Scott noted, when leaders operate in emotional isolation, they lose what he calls "social capital": the trust, rapport, and influence required for meaningful and effective leadership.
The health risks are serious. A study published in World Psychiatry found that isolation and a lack of social support increase the risk of burnout, anxiety, depression, and PTSD in professionals—no amount of success or compensation shields against this erosion.
High performance doesn't require abandoning your identity. Yet many men, in pursuit of growth and achievement, entirely sacrifice their hobbies, passions, and relationships, only to arrive at the top with fractured lives. Leaders rooted in their identity and a strong sense of self, rather than just achievement and accolades, tend to be more resilient. Organizations can support this by:
Men's Health in Corporate America
Men's health struggles don't show up on quarterly reports until it's too late. By then, they've already surfaced as stalled leadership pipelines, costly turnover, disengaged teams, and declining innovation. High-performing men aren't immune to exhaustion, disconnection, or identity loss. They're often the most skilled at hiding it. When that happens, companies not only lose talent but also trust, longevity, and untapped potential. Much like women's health, the well-being of your male leaders isn't just a personal matter; it's a business imperative. And it's also key to winning the future of work.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
18 minutes ago
- Yahoo
HCA Healthcare Foundation Awards $1 Million Grant to Educate Texas for Healthcare Career Pathways
HCA Healthcare Inc. (NYSE:HCA) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 26, HCA Healthcare announced that its HCA Healthcare Foundation, through its Healthier Tomorrow Fund, will provide a new $1 million grant to Educate Texas, which is an initiative of Communities Foundation of Texas. HCA Healthcare Foundation promotes health and well-being across all the communities HCA Healthcare serves The latest donation expands upon a previous $1.35 million grant made by the Foundation to Educate Texas in 2022. The funding aims to increase student access to programs that prepare them for careers in healthcare, specifically focusing on high schools in Texas that offer Pathways in Technology Early College High School (P-TECH) healthcare career tracks. The initial 2022 grant supported the expansion of healthcare career pathways across P-TECH campuses, growing from 20 to 104 schools and enrolling ~10,000 high school students in these specialized programs. A team of healthcare professionals in lab coats and masks meeting at a hospital ward. The new $1 million grant will enable Educate Texas to further enhance the quality of program implementation. The initiative seeks to increase the number of students earning healthcare degrees and credentials and foster greater engagement of hospital employers, including HCA Healthcare-affiliated hospitals, with school districts in North Texas, Austin, San Antonio, and the Houston Gulf Coast region. HCA Healthcare Inc. (NYSE:HCA) owns and operates hospitals and related healthcare entities in the US. While we acknowledge the potential of HCA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
BioMarin's ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most undervalued US stocks according to analysts. On June 24, BioMarin Pharmaceutical Inc. presented new 5-year data from its Phase 3 GENEr8-1 trial at the 33rd Congress of the International Society on Thrombosis and Haemostasis/ISTH in Washington, D.C., which took place from June 21 to 25. The data reinforced the long-term efficacy and safety of ROCTAVIAN (valoctocogene roxaparvovec-rvox) as a gene therapy for severe hemophilia A. The GENEr8-1 trial is the longest and largest hemophilia gene therapy study to date, and demonstrated sustained Factor VIII (FVIII) expression and durable bleed control 5 years after a single treatment with ROCTAVIAN. A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide. FVIII activity remained consistent with previously reported results. Importantly, no new safety signals were observed over the 5-year study period. Across all 134 participants who received ROCTAVIAN in the study, there were no cases of FVIII inhibitors or thromboembolic events, and no treatment-related malignancies were observed. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company that develops and commercializes therapies for life-threatening rare diseases and medical conditions internationally. While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio